Chinook Therapeutics, Inc. Debt to Equity Ratio 2015-2023 | KDNY
Current and historical debt to equity ratio values for Chinook Therapeutics, Inc. (KDNY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Chinook Therapeutics, Inc. debt/equity for the three months ending June 30, 2023 was .
| Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2023-06-30 | $0.13B | $0.36B | 0.37 |
| 2023-03-31 | $0.13B | $0.41B | 0.32 |
| 2022-12-31 | $0.13B | $0.44B | 0.30 |
| 2022-09-30 | $0.12B | $0.48B | 0.24 |
| 2022-06-30 | $0.09B | $0.51B | 0.19 |
| 2022-03-31 | $0.10B | $0.43B | 0.25 |
| 2021-12-31 | $0.11B | $0.45B | 0.24 |
| 2021-09-30 | $0.11B | $0.27B | 0.42 |
| 2021-06-30 | $0.11B | $0.30B | 0.38 |
| 2021-03-31 | $0.10B | $0.30B | 0.33 |
| 2020-12-31 | $0.09B | $0.34B | 0.28 |
| 2020-09-30 | $0.21B | $0.04B | 6.15 |
| 2020-06-30 | $0.22B | $0.05B | 4.69 |
| 2020-03-31 | $0.23B | $0.06B | 3.79 |
| 2019-12-31 | $0.06B | $-0.04B | -1.38 |
| 2019-09-30 | $0.23B | $0.08B | 2.82 |
| 2019-06-30 | $0.24B | $0.10B | 2.35 |
| 2019-03-31 | $0.24B | $0.12B | 2.08 |
| 2018-12-31 | $0.22B | $0.14B | 1.64 |
| 2018-09-30 | $0.21B | $0.16B | 1.34 |
| 2018-06-30 | $0.22B | $0.18B | 1.26 |
| 2018-03-31 | $0.23B | $0.20B | 1.15 |
| 2017-12-31 | $0.21B | $0.24B | 0.87 |
| 2017-09-30 | $0.21B | $0.26B | 0.81 |
| 2017-06-30 | $0.21B | $0.26B | 0.80 |
| 2017-03-31 | $0.21B | $0.23B | 0.90 |
| 2016-12-31 | $0.21B | $0.23B | 0.93 |
| 2016-09-30 | $0.22B | $0.25B | 0.87 |
| 2016-06-30 | $0.22B | $0.25B | 0.91 |
| 2016-03-31 | $0.23B | $0.24B | 0.95 |
| 2015-12-31 | $0.22B | $0.26B | 0.84 |
| 2015-09-30 | $0.22B | $0.24B | 0.88 |
| 2015-06-30 | $0.23B | $0.24B | 0.96 |
| 2015-03-31 | $0.05B | $0.09B | 0.58 |
| 2014-12-31 | $0.05B | $0.08B | 0.61 |
| 2014-09-30 | $0.00B | 0.00 | |
| 2014-06-30 | $0.00B | 0.00 | |
| 2014-03-31 | $0.00B | 0.00 | |
